MP35-02 MOLECULAR MECHANISM MEDIATING CYTOTOXIC ACTIVITY OF AXITINIB IN SUNITINIB-RESISTANT HUMAN RENAL CELL CARCINOMA CELLS

作者
Akira Miyazaki,Hideaki Miyake,Masato Fujisawa
出处
期刊:The Journal of Urology [Lippincott Williams & Wilkins]
卷期号:191 (4S)
标识
DOI:10.1016/j.juro.2014.02.1045
摘要

You have accessJournal of UrologyKidney Cancer: Basic Research III1 Apr 2014MP35-02 MOLECULAR MECHANISM MEDIATING CYTOTOXIC ACTIVITY OF AXITINIB IN SUNITINIB-RESISTANT HUMAN RENAL CELL CARCINOMA CELLS Akira Miyazaki, Hideaki Miyake, and Masato Fujisawa Akira MiyazakiAkira Miyazaki More articles by this author , Hideaki MiyakeHideaki Miyake More articles by this author , and Masato FujisawaMasato Fujisawa More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.1045AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Although axitinib and sunitinib are shown to exert antitumor activity against renal cell carcinoma (RCC) based on common mechanism characterized by the inhibition of tumor cell proliferation as well as angiogenesis through the inactivation of receptor tyrosine kinases, it has been well documented that axitinib still have a powerful therapeutic activity in patients with RCC who acquired resistance to sunitinib. The objective of this study was to clarify molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human RCC cells. METHODS A parental human RCC cell line, ACHN (ACHN/P), was continuously exposed to increasing doses of sunitinib, and a cell line resistant to sunitinib (ACHN/R), showing an approximately 5-fold higher IC50 than that of ACHN/P, was developed. Differences in molecular phenotypes following treatment with sunitinib or axitinib between these two cell lines were compared. RESULTS ACHN/R appeared to acquire significant cross resistance to another potential tyrosine kinase inhibitor, sorafenib; however, there were no significant differences in sensitivities to axitinib in addition to the Mammalian target of rapamycin inhibitors, temsirolimus and everolimus, between ACHN/P and ACHN/R. In ACHN/P, both sunitinib and axitinib markedly inhibited the expression levels of phosphorylated Akt, p44/42 mitogen activated protein kinase (MAPK) and vascular endothelial growth factor receptor-2 (VEGFR-2). In ACHN/R, however, phosphorylation of Akt, p44/42 MAPK and VEGFR-2 were maintained following treatment with sunitinib, whereas treatment with axitinib resulted in the marked down-regulation of both phosphorylated p44/42 MAPK and VEGFR-2, but not that of Akt. Furthermore, additional treatment with LY294002, a specific inhibitor of AKT, significantly increased the sensitivity of ACHN/R to axitinib, but not that of ACHN/P. In vivo growth of ACHN/R in nude mice following treatment with axitinib was also significantly suppressed compared with that following treatment with sunitinib. CONCLUSIONS These findings suggest that antitumor activity of axitinib in RCC cells even after the acquisition of resistance to sunitinib could be explained, at least in part, by the inactivation of p44/42 MAPK and VEGFR-2, which were persistently phosphorylated following treatment with sunitinib, and that combined administration of a specific inhibitor of Akt may further enhance the cytotoxic effect of axitinib on sunitinib-resistant human RCC cells. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e370-e371 Advertisement Copyright & Permissions© 2014Metrics Author Information Akira Miyazaki More articles by this author Hideaki Miyake More articles by this author Masato Fujisawa More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
收手吧大哥完成签到,获得积分10
刚刚
GAOYUwenzhang完成签到,获得积分10
刚刚
champ2ons完成签到,获得积分10
1秒前
SciGPT的应助被WJS采纳,获得10
1秒前
微血管发布了新的文献求助20
1秒前
wxnice发布了新的文献求助10
1秒前
阿张完成签到,获得积分10
1秒前
绵绵冰完成签到 ,获得积分10
2秒前
Awei完成签到,获得积分10
2秒前
伯赏迎松完成签到,获得积分10
2秒前
2秒前
e个汉堡包完成签到 ,获得积分10
4秒前
幼儿园老大完成签到,获得积分10
4秒前
4秒前
4秒前
hanxi完成签到,获得积分10
4秒前
xiaozhou完成签到,获得积分10
5秒前
YY完成签到,获得积分10
5秒前
5秒前
ykzhu完成签到,获得积分10
5秒前
涵青夏完成签到 ,获得积分10
5秒前
6秒前
6秒前
科研通AI6.4的应助被dabai采纳,获得10
6秒前
七七完成签到,获得积分10
6秒前
hermit的应助被lovesxj941采纳,获得110
6秒前
ZW完成签到,获得积分10
6秒前
jeong完成签到,获得积分10
6秒前
123完成签到,获得积分10
6秒前
Orange的应助被李佳会采纳,获得10
7秒前
7秒前
7秒前
7秒前
Solitary完成签到,获得积分10
7秒前
wxnice完成签到,获得积分10
8秒前
酷波er的应助被海盐奶盖采纳,获得10
9秒前
研友_VZG7GZ的应助被峥嵘采纳,获得10
9秒前
李白完成签到,获得积分10
9秒前
10秒前
huhuan完成签到,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180275
求助须知:如何正确求助?哪些是违规求助? 9570366
关于积分的说明 21810725
捐赠科研通 7776380
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479042